Premium
Single‐cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: What are the best predictors of remission and prognosis?
Author(s) -
Semrau Sabine,
Haderlein Marlen,
Schmidt Daniela,
Lell Michael,
Wolf Walburga,
Waldfahrer Frank,
Uder Michael,
Iro Heinrich,
Kuwert Torsten,
Fietkau Rainer
Publication year - 2015
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.29188
Subject(s) - medicine , induction chemotherapy , chemoradiotherapy , head and neck cancer , head and neck , chemotherapy , cancer , surgery , oncology
BACKGROUND There is controversy over the concept of function and organ preservation by chemotherapy/chemoradiation instead of surgery in locally advanced cancer of the larynx or pharynx. Tumor response to induction chemotherapy (ICT) can help in choosing between conservative and surgical treatment. This study compared 3 methods of assessing response to ICT: endoscopy, computed tomography, and 18 F‐FDG‐PET/CT. METHODS Primary response to 1 cycle of ICT with docetaxel plus platinum was assessed by the aforementioned methods in 62 laryngopharyngeal cancer patients. Endoscopic response was the deciding factor for selecting further treatment: surgery for endoscopic nonresponders (<30% tumor response) versus chemoradiotherapy for endoscopic responders. RESULTS ICT achieved endoscopic response in 48 of 62 patients (77%). Individual relative residual tumor activity of standardized uptake value (resSUV max ) in 18 F‐FDG‐PET/CT was a median 0.38 of baseline (0.09‐1.71), whereas residual tumor extent in CT (resCT) was 0.75 of baseline (0.32‐1.20). Endoscopic responders and nonresponders differed significantly in SUV max after ICT (postSUV max , 6.0 vs 14.5; P < .001), resSUV max (0.34 vs 0.81, P < .001), and resCT (0.71 vs 0.87, P = .004), but not in maximum tumor diameter after ICT (14 vs 20 mm, P = .11). resSUV max <0.8 and absolute postSUV max <10 provided the best discriminatory power for long‐term success criteria (tumor‐free survival, overall survival). CONCLUSIONS Metabolic tumor response showed very good correlation with clinical tumor response to ICT. The value of metabolic response detected by 18 F‐FDG‐PET/CT should be explored in a prospective clinical trial. Cancer 2015;121:1214–1222. © 2014 American Cancer Society .